Graham Lilley

Graham Lilley is an experienced professional in analytical development and process engineering within the biotechnology industry. Currently serving as the Director of Analytical Development at Affinia Therapeutics since May 2023, Graham previously held the position of Associate Director in Potency Analytical Development at Intellia Therapeutics, where expertise was applied in developing cell-based potency assays for various therapeutic modalities. Prior to that, a role as Senior Process Development Engineer at Caribou Biosciences involved the development of large-scale manufacturing processes for CRISPR-based CAR-T therapies. Graham's career began at bluebird bio, managing cGMP manufacturing for the FDA-approved CAR-T therapy bb2121 and optimizing its manufacturing process. Academic foundations include a Master’s degree in Cellular and Molecular Biology with a focus on Immunology from the University of Vermont and a Bachelor's degree in Biology from the University of Massachusetts Lowell.